Systematic review of measures of disease severity in rhinitis.
allergic rhinitis
disease severity
patient-reported outcome measure
quality of life
rhinitis
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
23
02
2021
received:
14
12
2020
accepted:
23
02
2021
pubmed:
28
3
2021
medline:
26
10
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
Rhinologists often encounter a broad spectrum of allergic rhinitis (AR) and nonallergic rhinitis (NAR) patients, who can be variably classified based upon timing and severity of disease. Our understanding of the varied quality of life (QOL) impact in different classifications of rhinitis is limited. Thus a more comprehensive understanding of the impact of rhinitis upon our patients, as measured by both patient reported outcome measures (PROMs) and clinical physiologic measures, as well as unique factors associated with disease severity is needed. A systematic search of databases was performed to identify AR and NAR studies reporting Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), total nasal symptom score (TNSS), or visual analogue scale (VAS) scores, and physiologic measures including peak nasal inspiratory flow (PNIF) and nasal airflow. Relationships between PROMs, physiologic measures, and associated factors (e.g., allergic status, disease duration) were assessed by weighted correlations and meta-regressions. A total of 171 studies reporting on 33,843 patients were included. Symptoms were more severe in AR than NAR on VAS (p < 0.001). Classification based upon Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines demonstrated differences in PROM severity. There was no significant correlation between PROMs and demographic factors, comorbidities, or physiologic measures. Meta-regression identified a correlation between worse RQLQ scores and shorter disease duration (r = -0.4, p < 0.001). Rhinitic patients have more severe impact upon QOL in the presence of allergy with variable impact upon specific symptom subdomains. PROMs do not correlate with common demographic factors, comorbidities, or physiologic measures of nasal airflow.
Sections du résumé
BACKGROUND
Rhinologists often encounter a broad spectrum of allergic rhinitis (AR) and nonallergic rhinitis (NAR) patients, who can be variably classified based upon timing and severity of disease. Our understanding of the varied quality of life (QOL) impact in different classifications of rhinitis is limited. Thus a more comprehensive understanding of the impact of rhinitis upon our patients, as measured by both patient reported outcome measures (PROMs) and clinical physiologic measures, as well as unique factors associated with disease severity is needed.
METHODS
A systematic search of databases was performed to identify AR and NAR studies reporting Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), total nasal symptom score (TNSS), or visual analogue scale (VAS) scores, and physiologic measures including peak nasal inspiratory flow (PNIF) and nasal airflow. Relationships between PROMs, physiologic measures, and associated factors (e.g., allergic status, disease duration) were assessed by weighted correlations and meta-regressions.
RESULTS
A total of 171 studies reporting on 33,843 patients were included. Symptoms were more severe in AR than NAR on VAS (p < 0.001). Classification based upon Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines demonstrated differences in PROM severity. There was no significant correlation between PROMs and demographic factors, comorbidities, or physiologic measures. Meta-regression identified a correlation between worse RQLQ scores and shorter disease duration (r = -0.4, p < 0.001).
CONCLUSION
Rhinitic patients have more severe impact upon QOL in the presence of allergy with variable impact upon specific symptom subdomains. PROMs do not correlate with common demographic factors, comorbidities, or physiologic measures of nasal airflow.
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1367-1377Informations de copyright
© 2021 ARS-AAOA, LLC.
Références
Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958.
Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112-2122.
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*: aRIA: 2008 update. Allergy. 2008;63:8-160.
Demoly P, Calderon MA, Casale T, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013;3(1):7.
Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010;104(1):13-29.
Klimek L, Bergmann K-C, Biedermann T, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017;26(1):16-24.
Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the rhinoconjunctivitis quality of life questionnaire. J Allergy Clin Immunol. 1999;104(2):364-369.
Araújo-Martins J, Brás-Geraldes C, Neuparth N. The potential role of peak nasal inspiratory flow to evaluate active sinonasal inflammation and disease severity. Sci Rep. 2020;10(1):12674.
Beattie E, Small C, Lorentz H, Nelson V, Couroux PR, Marie Salapatek A. Repeatability of total nasal symptom scores (TNSS) in allergic rhinitis individuals using an electronic diary during environmental exposure chamber (EEC) Visits. J Allergy Clin Immunol. 2018;141(2):AB403.
André RF, Vuyk HD, Ahmed A, Graamans K, Nolst Trenité GJ. Correlation between subjective and objective evaluation of the nasal airway. A systematic review of the highest level of evidence: subjective and objective evaluation of nasal patency. Clin Otolaryngol. 2009;34(6):518-525.
Moher D, Liberati A, Tetzlaff J, Altman DG; for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535-b2535.
Standardized Allergenic Extract, Timothy Grass (Phleum pratense) (GRASTEK) (Sublingual Tablet 2,800 BAU). Canadian Agency for Drugs and Technologies in Health; 2014. http://www.ncbi.nlm.nih.gov/books/NBK264137/. Accessed March 8, 2021.
Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal clinically important difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682-688.e6.
Sikorska-Szaflik H, Sozańska B. Peak nasal inspiratory flow in children with allergic rhinitis. Is it related to the quality of life?. Allergol Immunopathol (Madr). 2020;48(2):187-193.
Chin D, Marcells G, Malek J, et al. Nasal peak inspiratory flow (NPIF) as a diagnostic tool for differentiating decongestable from structural nasal obstruction. Rhinology. 2014;52(2):116-121.
Timperley D, Srubisky A, Stow N, Marcells GN, Harvey RJ. Minimal clinically important differences in nasal peak inspiratory flow. Rhinology. 2011;49(1):37-40.
Passali FM, Ottaviano G, Passali GC, Di Girolamo S. The Role of Rhinomanometry and Nasal Airflow Evaluation in the Diagnosis of Atrophic Rhinitis. In: Di Girolamo S, ed. Atrophic Rhinitis. Springer International Publishing; 2020:7
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell; 2008.
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372(5):456-463.
Nozad CH, Michael LM, Betty Lew D, Michael CF. Non-allergic rhinitis: a case report and review. Clin Mol Allergy. 2010;8(1):1.
Soler ZM, Nguyen SA, Salvador C, et al. A novel device combining acoustic vibration with oscillating expiratory pressure for the treatment of nasal congestion. Int Forum Allergy Rhinol. 2020;10(5):610-618.
Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160(4):393-400.
Starling-Schwanz R, Peake HL, Salome CM, et al. Repeatability of peak nasal inspiratory flow measurements and utility for assessing the severity of rhinitis. Allergy. 2005;60(6):795-800.
Neighbour H, Soliman M, Steacy LM, et al. The allergic rhinitis clinical investigator collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy. Clin Transl Allergy. 2018;8(1):15.
Cingi C, Gevaert P, Mösges R, et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017;7(1):17.
Spector S. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol. 1997;99(2):S773-S780.
Magnan A, Meunier JP, Saugnac C, Gasteau J, Neukirch F. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. Allergy. 2008;63(3):292-298.
Corren J. Allergic rhinitis and asthma: how important is the link?. J Allergy Clin Immunol. 1997;99(2):S781-S786.
Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013;10:E66.
Liu DT, Besser G, Prem B, et al. Self-perceived taste and flavor perception: associations with quality of life in patients with olfactory loss. [published online ahead of print October 13, 2020]. Otolaryngol Neck Surg. https://doi.org/10.1177/0194599820965242.
Liu DT, Besser G, Prem B, Speth MM, Sedaghat AR, Mueller CA. Individual importance of olfaction decreases with duration of smell loss. Rhinol J. 2021;59(1):32-39.
Belhassen M, Demoly P, Bloch-Morot E, et al. Costs of perennial allergic rhinitis and allergic asthma increase with severity and poor disease control. Allergy. 2017;72(6):948-958.
Halpern MT, Schmier JK, Richner R, Guo C, Togias A. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma. 2004;41(1):117-126.